Compare GSK Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PFIZER - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PFIZER GSK PHARMA/
PFIZER
 
P/E (TTM) x 51.9 41.5 124.9% View Chart
P/BV x 11.7 6.9 169.7% View Chart
Dividend Yield % 1.4 0.5 272.9%  

Financials

 GSK PHARMA   PFIZER
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
PFIZER
Mar-19
GSK PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,5953,840 93.6%   
Low Rs1,2532,080 60.2%   
Sales per share (Unadj.) Rs184.7455.0 40.6%  
Earnings per share (Unadj.) Rs26.393.8 28.0%  
Cash flow per share (Unadj.) Rs29.2109.4 26.7%  
Dividends per share (Unadj.) Rs20.0022.50 88.9%  
Dividend yield (eoy) %0.80.8 108.5%  
Book value per share (Unadj.) Rs126.3658.2 19.2%  
Shares outstanding (eoy) m169.4045.75 370.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.16.5 201.8%   
Avg P/E ratio x92.231.6 292.1%  
P/CF ratio (eoy) x83.127.1 307.2%  
Price / Book Value ratio x19.24.5 426.7%  
Dividend payout %76.124.0 317.0%   
Avg Mkt Cap Rs m410,626135,420 303.2%   
No. of employees `0005.02.6 188.5%   
Total wages/salary Rs m5,3723,238 165.9%   
Avg. sales/employee Rs Th6,306.77,911.4 79.7%   
Avg. wages/employee Rs Th1,083.11,230.9 88.0%   
Avg. net profit/employee Rs Th898.01,630.7 55.1%   
INCOME DATA
Net Sales Rs m31,28120,815 150.3%  
Other income Rs m1,0231,674 61.1%   
Total revenues Rs m32,30422,489 143.6%   
Gross profit Rs m6,0095,712 105.2%  
Depreciation Rs m486714 68.1%   
Interest Rs m673 8.2%   
Profit before tax Rs m6,5406,599 99.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,3732,309 102.8%   
Profit after tax Rs m4,4544,291 103.8%  
Gross profit margin %19.227.4 70.0%  
Effective tax rate %36.335.0 103.7%   
Net profit margin %14.220.6 69.1%  
BALANCE SHEET DATA
Current assets Rs m20,06127,167 73.8%   
Current liabilities Rs m14,5438,917 163.1%   
Net working cap to sales %17.687.7 20.1%  
Current ratio x1.43.0 45.3%  
Inventory Days Days5768 83.7%  
Debtors Days Days1430 46.7%  
Net fixed assets Rs m14,3438,862 161.8%   
Share capital Rs m1,694458 370.3%   
"Free" reserves Rs m19,70429,656 66.4%   
Net worth Rs m21,39830,113 71.1%   
Long term debt Rs m225 8.0%   
Total assets Rs m39,11339,400 99.3%  
Interest coverage x1,091.091.5 1,192.1%   
Debt to equity ratio x00 11.3%  
Sales to assets ratio x0.80.5 151.4%   
Return on assets %11.411.1 103.0%  
Return on equity %20.814.2 146.1%  
Return on capital %31.922.1 144.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m534428 124.7%   
Fx outflow Rs m7,091786 901.7%   
Net fx Rs m-6,557-358 1,831.1%   
CASH FLOW
From Operations Rs m3,994978 408.3%  
From Investments Rs m-1,433351 -408.1%  
From Financial Activity Rs m-3,584-1,099 326.2%  
Net Cashflow Rs m-1,023231 -443.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 63.9 79.3%  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 4.9 485.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.7 65.0%  
Shareholders   102,036 85,207 119.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 25, 2021 03:36 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - STERLING BIOTECH COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS